{"nctId":"NCT01496274","briefTitle":"A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","startDateStruct":{"date":"2012-02"},"conditions":["Hemophilia B"],"count":63,"armGroups":[{"label":"Prophylaxis","type":"EXPERIMENTAL","interventionNames":["Biological: rIX-FP"]},{"label":"On-demand","type":"EXPERIMENTAL","interventionNames":["Biological: rIX-FP"]}],"interventions":[{"name":"rIX-FP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male subjects, 12 to 65 years old\n* Severe hemophilia B (FIX activity of ≤ 2%)\n* Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for \\> 150 exposure days (EDs)\n* No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX\n* Written informed consent for study participation\n* On-demand subjects only, who have experienced a minimum average of 2 non-trauma induced bleeding episodes requiring treatment with a FIX product during the previous 6 or 3 months\n\nExclusion Criteria:\n\n* Known hypersensitivity to any FIX product or hamster protein\n* Known congenital or acquired coagulation disorder other than congenital FIX deficiency\n* HIV positive subjects with a CD4 count \\< 200/mm3\n* Low platelet count, kidney or liver dysfunction\n* Recent life-threatening bleeding episode","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Frequency of Spontaneous Bleeding Events Between On-demand and Prophylaxis Treatments (Annualized)","description":"Subjects in the on-demand arm received on-demand dosing with rIX-FP for up to 26 weeks (on-demand regimen), and then received weekly prophylaxis with rIX-FP for the remainder of the study (prophylaxis regimen). The effectiveness of prophylaxis in comparison to on-demand therapy was investigated by comparing the same subject's annualized spontaneous bleeding rate (AsBR) during the on-demand regimen and during the prophylaxis regimen.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.43","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Developing Inhibitors Against Factor IX (FIX)","description":"The number of participants developing inhibitors against factor IX (FIX) along with the 95% Clopper-Pearson confidence interval, are summarized for subjects with 50 or more exposure days (EDs) to rIX-FP, and for all participants in the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Frequency of Related Adverse Events","description":"The percentage of participants experiencing treatment-related adverse-events (TEAEs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"4.3","spread":null},{"groupId":"OG002","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"78.3","spread":null},{"groupId":"OG002","value":"84.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Developing Antibodies Against rIX-FP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Bleeding Episodes Requiring One or ≤ Two Injections of rIX-FP to Achieve Hemostasis","description":"Number of injections required to achieve hemostasis expressed as a percentage of the bleeding episodes requiring treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"94.5","spread":null},{"groupId":"OG002","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.6","spread":null},{"groupId":"OG002","value":"94.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Overall Clinical Assessment of Hemostatic Efficacy for Treatment of Bleeding Episodes, Based on a Four Point Ordinal Scales (Excellent, Good, Moderate, Poor/No Response)","description":"Number of bleeding episodes requiring treatment that resulted in hemostatic efficacy of excellent, good, moderate, poor/no response, according to the Investigator's clinical assessment of hemostatic efficacy, expressed as a percentage of the bleeding episodes requiring treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"rIX-FP Consumed Per Month While Maintaining Assigned Prophylactic Treatment Interval During Routine Prophylaxis.","description":"Time frame: For Prophylaxis Arm 7-, 10- and 14-day regimens, median 269, 240 and 386 days respectively. For On-demand Arm, prophylaxis regimen, median 316 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191.69","spread":"36.33"},{"groupId":"OG001","value":"202.68","spread":"47.92"},{"groupId":"OG002","value":"201.50","spread":"42.56"},{"groupId":"OG003","value":"157.44","spread":"16.34"}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery of rIX-FP","description":"Pharmacokinetic (PK) data are presented for a single 50 IU/kg dose of rIX-FP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":"0.33"},{"groupId":"OG001","value":"1.24","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Half-life (t1/2) of a Single Dose of rIX-FP","description":"PK data are presented for a single 50 IU/kg dose of rIX-FP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.77","spread":"22.73"},{"groupId":"OG001","value":"96.88","spread":"20.94"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC)","description":"AUC to the last sample with quantifiable drug concentration (AUClast) of a single dose of rIX-FP. PK data are presented for a single 50 IU/kg dose of rIX-FP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6534.15","spread":"1856.96"},{"groupId":"OG001","value":"5963.30","spread":"1893.00"}]}]}]},{"type":"SECONDARY","title":"Clearance of a Single Dose of rIX-FP","description":"PK data are presented for a single 50 IU/kg dose of rIX-FP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.19","spread":"12.92"},{"groupId":"OG001","value":"59.00","spread":"19.37"}]}]}]},{"type":"SECONDARY","title":"Investigator's (or Surgeon's) Overall Clinical Assessment of Hemostatic Efficacy for Surgical Prophylaxis, Based on a Four Point Ordinal Scale (Excellent, Good, Moderate, Poor/No Response)","description":"Number of surgical events treated prophylactically with rIX-FP that resulted in hemostatic efficacy of excellent, good, moderate, poor/no response, according to the Investigator's (surgeon's) overall assessment of hemostatic efficacy for surgical prophylaxis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Spontaneous Bleeding Events Compared Between 7 Day Prophylactic and Extended Regimens","description":"Median number of spontaneous bleeds per year per subject comparing 7-, 10- and 14- day prophylactic regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":["NASOPHARYNGITIS","HEADACHE","ARTHRALGIA","INFLUENZA","LIMB INJURY"]}}}